MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

• Status: Active, not recruiting
• Trial end date: 2023-05-15
• Target enrollment: 0
• Participant gender: All

Summary

This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H5.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota
• Collaborators: AIDS Clinical Trials Group; Cardiothoracic Surgical Trials Network (CTSN); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT); Kirby Institute; Medical Research Council; Molecular Partners AG; National Heart, Lung, and Blood Institute (NHLBI); Prevention and Early Treatment of Acute Lung Injury (PETAL); University of Copenhagen; US Department of Veterans Affairs; Washington D.C. Veterans Affairs Medical Center
• Treatments: Remdesivir

Criteria

Inclusion Criteria: Refer to the master protocol (NCT04501978)

Exclusion Criteria: Refer to the master protocol (NCT04501978)

Additional Exclusion Criteria:

1. Pregnant women

2. Nursing mothers

3. Women of child-bearing potential who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with men or practice appropriate contraception through 11 weeks after receiving MP0420/placebo

4. Men who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through 11 weeks after receiving MP0420/placebo.